Axsome Therapeutics Inc AXSM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AXSM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $71.52
- Day Range
- $69.70–72.43
- 52-Week Range
- $55.02–98.40
- Bid/Ask
- $71.00 / $72.75
- Market Cap
- $3.40 Bil
- Volume/Avg
- 272,333 / 735,350
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 422
- Website
- https://www.axsome.com
Profitability
|
Metric
|
AXSM
|
IMVT
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −29.97% | −43.33% | 20.67% |
Return on Equity (Normalized) | −78.66% | −47.83% | 23.56% |
Return on Invested Capital (Normalized) | −41.49% | −52.69% | 23.38% |
Return on Assets
AXSM
IMVT
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yggwttqns | Fzsww | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mwfdhpzn | Pbhlvc | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cqdtjhkqt | Thlxp | $97.8 Bil | |
MRNA
| Moderna Inc | Gqfmvrdm | Tnbs | $41.3 Bil | |
ARGX
| argenx SE ADR | Zctzccdp | Nmbcr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ppjrrkxd | Jjbfy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vltjrgl | Vdlyh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kqjmhjmnt | Wxtccq | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gkmdffhhy | Npfsxv | $12.5 Bil | |
INCY
| Incyte Corp | Xzjgytgxh | Xqpzkq | $11.6 Bil |